MAPK3 and neoplasm: However, TNO155 was able to improve the efficacy of trametinib (~30% tumor reduction for trametinib alone vs. ~53% reduction in combination with TNO155), likely through the abolishing of the p-ERK1/2 rebound mechanism (Figure 6E and Supplemental Figure 6B).